91 related articles for article (PubMed ID: 10408339)
1. V3 loop-derived peptide SPC3 inhibits infection of CD4- and galactosylceramide- cells by LAV-2/B.
Moulard M; Mabrouk K; Martin I; Van Rietschoten J; Rochat H; Sabatier JM
J Pept Res; 1999 Jun; 53(6):647-55. PubMed ID: 10408339
[TBL] [Abstract][Full Text] [Related]
2. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms.
Yahi N; Fantini J; Baghdiguian S; Mabrouk K; Tamalet C; Rochat H; Van Rietschoten J; Sabatier JM
Proc Natl Acad Sci U S A; 1995 May; 92(11):4867-71. PubMed ID: 7761414
[TBL] [Abstract][Full Text] [Related]
3. SPC3, a V3 loop-derived synthetic peptide inhibitor of HIV-1 infection, binds to cell surface glycosphingolipids.
Delézay O; Hammache D; Fantini J; Yahi N
Biochemistry; 1996 Dec; 35(49):15663-71. PubMed ID: 8961929
[TBL] [Abstract][Full Text] [Related]
4. SPC3, an anti-HIV peptide construct derived from the viral envelope, binds and enters HIV target cells.
Barbouche R; Miquelis R; Sabatier JM; Fenouillet E
J Pept Sci; 1998 Dec; 4(8):479-85. PubMed ID: 9927254
[TBL] [Abstract][Full Text] [Related]
5. Correlation of antiviral activity with beta-turn types for V3 synthetic multibranched peptides from HIV-1 gp120.
Mabrouk K; Van Rietschoten J; Rochat H; Loret EP
Biochemistry; 1995 Jul; 34(26):8294-8. PubMed ID: 7599121
[TBL] [Abstract][Full Text] [Related]
6. Suramin inhibits binding of the V3 region of HIV-1 envelope glycoprotein gp120 to galactosylceramide, the receptor for HIV-1 gp120 on human colon epithelial cells.
Yahi N; Sabatier JM; Nickel P; Mabrouk K; Gonzalez-Scarano F; Fantini J
J Biol Chem; 1994 Sep; 269(39):24349-53. PubMed ID: 7929093
[TBL] [Abstract][Full Text] [Related]
7. Synthetic multimeric peptides derived from the principal neutralization domain (V3 loop) of human immunodeficiency virus type 1 (HIV-1) gp120 bind to galactosylceramide and block HIV-1 infection in a human CD4-negative mucosal epithelial cell line.
Yahi N; Sabatier JM; Baghdiguian S; Gonzalez-Scarano F; Fantini J
J Virol; 1995 Jan; 69(1):320-5. PubMed ID: 7983725
[TBL] [Abstract][Full Text] [Related]
8. Ion channel activation by SPC3, a peptide derived from the HIV-1 gp120 V3 loop.
Carlier E; Mabrouk K; Moulard M; Fajloun Z; Rochat H; De Waard M; Sabatier JM
J Pept Res; 2000 Dec; 56(6):427-37. PubMed ID: 11152302
[TBL] [Abstract][Full Text] [Related]
9. Properties of HIV envelope expressed in the presence of SPC3, an Env-derived peptide drug under phase II clinical trials.
Barbouche R; Fenouillet E; Papandréou MJ; Kiény MP; Sabatier JM
J Pept Res; 1998 Oct; 52(4):283-8. PubMed ID: 9832306
[TBL] [Abstract][Full Text] [Related]
10. A post-CD4-binding step involving interaction of the V3 region of viral gp120 with host cell surface glycosphingolipids is common to entry and infection by diverse HIV-1 strains.
Nehete PN; Vela EM; Hossain MM; Sarkar AK; Yahi N; Fantini J; Sastry KJ
Antiviral Res; 2002 Dec; 56(3):233-51. PubMed ID: 12406507
[TBL] [Abstract][Full Text] [Related]
11. Multibranched peptide constructs derived from the V3 loop of envelope glycoprotein gp120 inhibit human immunodeficiency virus type 1 infection through interaction with CD4.
Benjouad A; Chapuis F; Fenouillet E; Gluckman JC
Virology; 1995 Jan; 206(1):457-64. PubMed ID: 7831801
[TBL] [Abstract][Full Text] [Related]
12. Multibranched V3 peptides inhibit human immunodeficiency virus infection in human lymphocytes and macrophages.
Yahi N; Fantini J; Mabrouk K; Tamalet C; de Micco P; van Rietschoten J; Rochat H; Sabatier JM
J Virol; 1994 Sep; 68(9):5714-20. PubMed ID: 8057453
[TBL] [Abstract][Full Text] [Related]
13. Role of the HIV type 1 glycoprotein 120 V3 loop in determining coreceptor usage.
Verrier F; Borman AM; Brand D; Girard M
AIDS Res Hum Retroviruses; 1999 May; 15(8):731-43. PubMed ID: 10357469
[TBL] [Abstract][Full Text] [Related]
14. Synthetic soluble analogs of galactosylceramide (GalCer) bind to the V3 domain of HIV-1 gp120 and inhibit HIV-1-induced fusion and entry.
Fantini J; Hammache D; Delézay O; Yahi N; André-Barrès C; Rico-Lattes I; Lattes A
J Biol Chem; 1997 Mar; 272(11):7245-52. PubMed ID: 9054420
[TBL] [Abstract][Full Text] [Related]
15. Interactions of CCR5 and CXCR4 with CD4 and gp120 in human blood monocyte-derived dendritic cells.
Xiao X; Kinter A; Broder CC; Dimitrov DS
Exp Mol Pathol; 2000 Jun; 68(3):133-8. PubMed ID: 10816381
[TBL] [Abstract][Full Text] [Related]
16. Specific interaction of HIV-1 and HIV-2 surface envelope glycoproteins with monolayers of galactosylceramide and ganglioside GM3.
Hammache D; Piéroni G; Yahi N; Delézay O; Koch N; Lafont H; Tamalet C; Fantini J
J Biol Chem; 1998 Apr; 273(14):7967-71. PubMed ID: 9525894
[TBL] [Abstract][Full Text] [Related]
17. SPC3, a nontoxic peptide inhibitor of HIV infection.
Sabatier JM; Baghdiguian S; Yahi N; Rochat H; Van Rietschoten J; Fantini J
In Vitro Cell Dev Biol Anim; 1995 Jun; 31(6):415-8. PubMed ID: 8589880
[No Abstract] [Full Text] [Related]
18. Functional complementation of the envelope hypervariable V3 loop of human immunodeficiency virus type 1 subtype B by the subtype E V3 loop.
Sato H; Kato K; Takebe Y
Virology; 1999 May; 257(2):491-501. PubMed ID: 10329559
[TBL] [Abstract][Full Text] [Related]
19. Role of V3 independent domains on a dualtropic human immunodeficiency virus type 1 (HIV-1) envelope gp120 in CCR5 coreceptor utilization and viral infectivity.
Foda M; Harada S; Maeda Y
Microbiol Immunol; 2001; 45(7):521-30. PubMed ID: 11529558
[TBL] [Abstract][Full Text] [Related]
20. Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.
Means RE; Matthews T; Hoxie JA; Malim MH; Kodama T; Desrosiers RC
J Virol; 2001 Apr; 75(8):3903-15. PubMed ID: 11264379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
